Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555019 | 1.00 | FKBP1A (0.66) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL30165596 | 1.00 | FKBP1A (0.66) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL1540219 | 0.89 | SMN1; SMN2 (0.55) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL1540452 | 0.88 | SMN1; SMN2 (0.57) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL1540649 | 0.85 | FKBP1A (0.47) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL22581279 | 0.84 | RAB9A (0.49) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL22581278 | 0.84 | RAB9A (0.49) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL1540276 | 0.84 | FKBP1A (0.46) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL1540464 | 0.81 | ALDH1A1 (0.44) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 | |
| SCHEMBL22951074 | 0.81 | DPP4 (0.64) | FKBP1ASMN1; SMN2RAB9ANPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368603-A1 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-4392397-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| CN-118139835-A | Method for preparing apoptosis inducer | 艾伯维公司 | 2024-06-04 | — | — | CN | claimed |
| WO-2023028558-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20250368603-A1 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4392397-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118139835-A | Method for preparing apoptosis inducer | 艾伯维公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023028558-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023028558-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| EP-1765778-B1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368603-A1 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | BAX, CASP3, AIFM1 | FKBP1A 1753/4885SMN1; SMN2 3606/4885RAB9A 3961/4885 |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | FKBP1A 760/4885SMN1; SMN2 808/4885RAB9A 4492/4885 |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | FKBP1A 412/4885SMN1; SMN2 964/4885RAB9A 3031/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | FKBP1A 760/4885SMN1; SMN2 808/4885RAB9A 4492/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | FKBP1A 441/4885SMN1; SMN2 4406/4885RAB9A 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.